按蚊通过含药血餐摄入长效抗疟药但不付出适合度代价
该研究用补充了生理浓度长效抗疟药的血餐喂养实验室饲养的冈比亚按蚊和野外采集的科卢齐按蚊,评估药物暴露对蚊虫适合度的影响及药物吸收程度。结果显示阿莫地喹、去乙基阿莫地喹、哌喹和磺胺多辛-乙胺嘧啶未显著改变蚊虫摄食、行为、繁殖力或存活率,但液相色谱-串联质谱证实去乙基阿莫地喹在蚊虫全虫、中肠和血淋巴中呈剂量依赖性分布。
要点
- 按蚊多次吸血可反复摄入人血中的长效抗疟药,但所测药物未影响其适合度。
- 去乙基阿莫地喹可在蚊虫全虫、中肠和血淋巴中检出,提示药物可进入蚊虫循环。
- 该结果为后续评估蚊体内药物暴露对疟原虫发育及耐药选择的影响奠定基础。
核心结论
- 按蚊摄入含长效抗疟药的血餐后可吸收药物并持续存在于血淋巴,但未观察到适合度代价。
研究设计与样本
- 实验室研究:用补充生理浓度长效抗疟药的血餐喂养实验室饲养的冈比亚按蚊和野外采集的科卢齐按蚊。
- 采用液相色谱-串联质谱检测蚊虫全虫、中肠和血淋巴中的药物分布。
主要发现
- 阿莫地喹、去乙基阿莫地喹、哌喹和磺胺多辛-乙胺嘧啶未显著改变蚊虫摄食、行为、繁殖力或存活率。
- 去乙基阿莫地喹按半数及两倍报告Cmax浓度喂养后,在混合全蚊、中肠和血淋巴中呈剂量依赖性检出。
- 全蚊在24和120小时、中肠在24小时的检出差异有统计学意义。
- 24至120小时之间,中肠内药物减少而血淋巴中药物增加。
临床怎么用
- 提示蚊虫吸血时可摄入人血中的长效抗疟药且不损害自身适合度,需关注药物对蚊体内疟原虫发育和耐药选择的潜在影响。
局限性
- 研究为实验室条件,使用补充药物的血餐模拟生理暴露,尚未评估感染蚊体内疟原虫发育。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The World Health Organization's recommendations for antimalarial chemoprevention and mass treatment use in endemic areas have greatly expanded, allowing more flexibility in demographic groups and regions targeted. An overlooked aspect of expanding human population-level drug exposure is the downstream impact of a drug on the vector. Anopheles mosquitoes refeed often with ≥ 4 bloodmeals during their lifespan. This provides repeated opportunities for mosquitoes to ingest a drug via bloodmeals taken from people with antimalarials in the bloodstream and raises questions as to the drug's impact on mosquitoes. METHODS: We supplemented bloodmeals with physiologic levels of long-acting antimalarials to assess drug exposure impact on Anopheles mosquito fitness and determine drug absorption extent. RESULTS: We did not observe any significant differences in mosquito feeding, behavior, fecundity, or viability after amodiaquine, desethylamodiaquine, piperaquine, and sulfadoxine-pyrimethamine ingestion in laboratory-reared Anopheles gambiae or field-derived Anopheles coluzzii mosquitoes. Interrogating drug distribution within mosquitoes utilizing liquid chromatography-tandem mass spectrometry, desethylamodiaquine, amodiaquine's longer-acting active metabolite, was fed at half and twice reported Cmax concentrations; the drug was dose-dependently detected in pooled whole mosquitoes, midguts, and hemolymph. This was statistically significant for whole mosquitoes harvested at 24 and 120 hours, and midguts harvested at 24 hours. Between 24 and 120 hours, the drug decreased in midguts but increased in hemolymph. CONCLUSIONS: We show sustained biochemical evidence of antimalarial absorption into Anopheles hemolymph following bloodmeal ingestion without fitness costs. These studies provide a foundation to next assess vector-stage antimalarial drug exposure impact on parasite development in infected mosquitoes, which could in turn have implications for transmission dynamics and drug resistance spread. Drug resistance to first-line antimalarials has emerged independently and spread in multiple African countries. Better understanding of the factors underlying antimalarial resistance is critical. Millions regularly receive antimalarials for prophylaxis and mass treatment that are purposefully long acting. Anopheles mosquitoes (both infected and uninfected) refeed frequently, including feeding on people whose blood contains these long-acting antimalarials. Parasites take approximately 10 days to develop within the mosquito. There is published precedent that several antimalarials can act upon vector-stage parasites, yet any potential impact of antimalarials on mosquitoes and/or parasites developing within has been largely overlooked. We question whether antimalarials ingested in mosquito bloodmeals could influence parasite development and drug resistance selection. As initial investigations, we exposed uninfected Anopheles mosquitoes to commonly used long-acting antimalarials via drug-supplemented bloodmeals, mimicking predicted physiologic drug exposure. Investigated drugs did not impact mosquito viability. However, mass spectrometry confirmed drug absorption in whole mosquitoes, as well as isolated midguts and circulatory fluid, several days after feeding, demonstrating that mosquitoes can ingest key drugs without suffering fitness costs, and these drugs can persist in mosquito circulation and tissues. This highlights the potential for antimalarials to impact parasite development and resistance selection within the mosquito, an area of future investigation.
引用
- Goheen MM, Orfanó A, Dah SR, et al. Anopheles Mosquitoes Exposed to Long-Acting Antimalarials via Drug-Supplemented Bloodmeal Absorb Drug but Do Not Suffer Fitness Costs. J Infect Dis. 2026. PMID: 42296192. doi:10.1093/infdis/jiag300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。